Obesity and Diabetes mellitus Typ 2 research hub

Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degrees of renal impairment and normal renal function.

This study is looking at a new medicine, NNC0487-0111, for people with obesity and type 2 diabetes. We want to see how the body handles the medicine, how safe it is, and if people can tolerate it, especially those with kidney problems.